Asks New Members to Join Congressional Dietary Supplement Caucus
WASHINGTON – The Natural Products Association (NPA) in a letter to new Members of the 117th Congress, expressed concern about the lack of action from the Food and Drug Administration (FDA) on CBD enforcement, and warned about the dangers of allowing counterfeit products from entering the U.S. NPA has repeatedly asked the FDA to use its authority to set a safe level of daily consumption for CBD and for the FDA to use its authority to issue import alerts for fraudulent products.
“We recognize the historical challenges policymakers are facing during the pandemic. However, the COVID-19 crisis should not preclude the FDA from executing its important responsibilities in other areas. We welcome the new Congress and look forward to getting to work on issues that are critical to the health and safety of millions of Americans,” said Daniel Fabricant, Ph.D., President and CEO of NPA.
NPA also asked new members to join the Congressional Dietary Supplements Caucus, which is co-chaired by Senators Tim Scott (R-SC) and Martin Heinrich (D-NM) and Representatives Tony Cardenas (D-CA-29) and Andy Harris (R-MD-01).
NPA’s letter to new Members of Congress can be viewed here.
